Patent intelligence · US
US 11565096
Delivery system for a pharmaceutical, holistic or medicinal component
Delivery system for a pharmaceutical, holistic or medicinal component
Patent details — US 11565096
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2023
- Expiration
- Jan 26, 2043
- Applicant
- Herphoric, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K31/05, A61K31/658, A61K9/0036
Quick answer
US 11565096 (Delivery system for a pharmaceutical, holistic or medicinal component) is held by Herphoric, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Herphoric, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/05, A61K31/658, A61K9/0036, A61K9/025
More from Herphoric, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 11565096?
US 11565096 (Delivery system for a pharmaceutical, holistic or medicinal component) is held by Herphoric, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11565096?
Herphoric, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 11565096 expire?
Our index shows an expiration date of Jan 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.